Sara Tolaney/X
Jun 4, 2025, 09:58
Transformative study for 1st line Metastatic HER2+ Breast Cancer at ASCO25
Chandler Park, Advisory Dean and Clinical Professor at University of Louisville School of Medicine, shared a post on LinkedIn:
“Congratulations to Dr. Sara Tolaney, Dana-Farber Cancer Institute and the Destiny Breast09 investigators for a Trasnformative study for 1st line metastatic HER2+ breast cancer at ASCO25.
Really enjoyed talking to Dr. Giuseppe Curigliano on the HER2 story that started in Orlando about 20 years ago.”
Chandler Park acknowledged the impact of the DESTINY-Breast09 trial presented at ASCO 2025, recognizing Dr. Sara Tolaney and the investigative team for advancing treatment in first-line metastatic HER2-positive breast cancer.
More posts featuring Chandler Park.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Aug 8, 2025, 21:29
Aug 8, 2025, 21:08
Aug 8, 2025, 20:54
Aug 8, 2025, 20:18
Aug 8, 2025, 20:03
Aug 8, 2025, 19:51
Aug 8, 2025, 19:34